Imipenem
- Generic Name
- Imipenem
- Brand Names
- Primaxin, Recarbrio
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N3O4S
- CAS Number
- 64221-86-9
- Unique Ingredient Identifier
- Q20IM7HE75
- Background
Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ert...
- Indication
Imipenem is indicated, in combination with cilastatin with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.
- Associated Conditions
- Bacterial Septicemia, Bone and Joint Infections, Complicated Intra-Abdominal Infections (cIAIs) caused by Gram-negative Bacteria, Complicated Urinary Tract Infection, Complicated Urinary Tract Infection caused by Gram-negative Bacteria, Endocarditis caused by staphylococcus aureus, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Nosocomial Pneumonia caused by Gram-negative Bacteria, Pyelonephritis, Skin and Subcutaneous Tissue Bacterial Infections, Uncomplicated Urinary Tract Infections, Ventilator Associated Bacterial Pneumonia caused by Gram-negative Bacteria
- Associated Therapies
- -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 6
- Registration Number
- NCT02474706
- Locations
- 🇫🇷
CHRU Nancy, Nancy, France
Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 12
- Registration Number
- NCT02213783
- Locations
- 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 96
- Registration Number
- NCT01820026
- Locations
- 🇮🇹
Manuela Merli, Rome, Italy
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 123
- Registration Number
- NCT01714570
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, Beijing, China
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 563
- Registration Number
- NCT01659866
- Locations
- 🇺🇸
Northwestern University Department of Urology, Chicago, Illinois, United States
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Sutep Jaruratanasirikul
- Target Recruit Count
- 9
- Registration Number
- NCT01489124
- Locations
- 🇹🇭
Prince of Songkla University, Hat Yai, Songkla, Thailand
Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 8
- Registration Number
- NCT01379157
- Locations
- 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
- Conditions
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2008-08-04
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 430
- Registration Number
- NCT00080496
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.